<DOC>
	<DOCNO>NCT01359163</DOCNO>
	<brief_summary>A pivotal study determine bioequivalence current market formulation Femulen tablet reformulate Femulen tablet healthy female subject .</brief_summary>
	<brief_title>A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ethynodiol Diacetate</mesh_term>
	<criteria>Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 45 kg ( 99 lb ) . Healthy female subject age 21 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>bioequivalence study</keyword>
	<keyword>market vs reformulation tablet</keyword>
	<keyword>Femulen</keyword>
</DOC>